Verastem (VSTM) Competitors $3.92 +0.16 (+4.26%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends VSTM vs. MEIP, EPZM, EBS, LXRX, XOMA, SGMO, VNDA, RIGL, CDXS, and ACHVShould you be buying Verastem stock or one of its competitors? The main competitors of Verastem include MEI Pharma (MEIP), Epizyme (EPZM), Emergent BioSolutions (EBS), Lexicon Pharmaceuticals (LXRX), XOMA (XOMA), Sangamo Therapeutics (SGMO), Vanda Pharmaceuticals (VNDA), Rigel Pharmaceuticals (RIGL), Codexis (CDXS), and Achieve Life Sciences (ACHV). These companies are all part of the "medical" sector. Verastem vs. MEI Pharma Epizyme Emergent BioSolutions Lexicon Pharmaceuticals XOMA Sangamo Therapeutics Vanda Pharmaceuticals Rigel Pharmaceuticals Codexis Achieve Life Sciences Verastem (NASDAQ:VSTM) and MEI Pharma (NASDAQ:MEIP) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, community ranking, earnings, valuation, profitability, dividends, media sentiment and institutional ownership. Do analysts recommend VSTM or MEIP? Verastem presently has a consensus price target of $14.57, indicating a potential upside of 271.72%. MEI Pharma has a consensus price target of $7.00, indicating a potential upside of 128.01%. Given Verastem's stronger consensus rating and higher possible upside, equities research analysts plainly believe Verastem is more favorable than MEI Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Verastem 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00MEI Pharma 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has more volatility & risk, VSTM or MEIP? Verastem has a beta of 0.14, suggesting that its stock price is 86% less volatile than the S&P 500. Comparatively, MEI Pharma has a beta of 0.85, suggesting that its stock price is 15% less volatile than the S&P 500. Does the MarketBeat Community believe in VSTM or MEIP? Verastem received 210 more outperform votes than MEI Pharma when rated by MarketBeat users. Likewise, 65.20% of users gave Verastem an outperform vote while only 61.84% of users gave MEI Pharma an outperform vote. CompanyUnderperformOutperformVerastemOutperform Votes60765.20% Underperform Votes32434.80% MEI PharmaOutperform Votes39761.84% Underperform Votes24538.16% Which has better earnings and valuation, VSTM or MEIP? MEI Pharma has higher revenue and earnings than Verastem. Verastem is trading at a lower price-to-earnings ratio than MEI Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVerastem$2.60M60.67-$87.37M-$3.34-1.17MEI Pharma$65.30M0.31$17.78M$2.671.15 Is VSTM or MEIP more profitable? MEI Pharma's return on equity of 51.00% beat Verastem's return on equity.Company Net Margins Return on Equity Return on Assets VerastemN/A -194.05% -64.48% MEI Pharma N/A 51.00%39.23% Do insiders & institutionals believe in VSTM or MEIP? 88.4% of Verastem shares are owned by institutional investors. Comparatively, 52.4% of MEI Pharma shares are owned by institutional investors. 2.2% of Verastem shares are owned by insiders. Comparatively, 3.9% of MEI Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Does the media prefer VSTM or MEIP? In the previous week, MEI Pharma had 1 more articles in the media than Verastem. MarketBeat recorded 1 mentions for MEI Pharma and 0 mentions for Verastem. Verastem's average media sentiment score of 0.38 beat MEI Pharma's score of -0.36 indicating that Verastem is being referred to more favorably in the media. Company Overall Sentiment Verastem Neutral MEI Pharma Neutral SummaryMEI Pharma beats Verastem on 9 of the 17 factors compared between the two stocks. Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Get Verastem News Delivered to You Automatically Sign up to receive the latest news and ratings for VSTM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VSTM vs. The Competition Export to ExcelMetricVerastemPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$157.74M$7.03B$5.40B$8.53BDividend YieldN/A7.96%5.13%4.14%P/E Ratio-1.179.93115.5615.18Price / Sales60.67381.421,484.3492.77Price / CashN/A47.3439.6634.07Price / Book1.735.324.665.02Net Income-$87.37M$153.56M$119.06M$225.46M7 Day Performance23.27%0.11%0.80%0.37%1 Month Performance34.71%15.22%5.65%3.57%1 Year Performance-39.13%41.14%36.76%29.44% Verastem Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VSTMVerastem3.4491 of 5 stars$3.92+4.3%$14.57+271.7%-37.9%$157.74M$2.60M-1.1750Gap UpMEIPMEI Pharma4.5633 of 5 stars$2.73flat$7.00+156.4%-56.3%$18.18M$65.30M1.02100Analyst ForecastNews CoverageGap DownHigh Trading VolumeEPZMEpizymeN/A$1.47flatN/A+0.0%$247.44M$37.43M-0.85250Analyst ForecastEBSEmergent BioSolutions4.3493 of 5 stars$8.93-1.4%$12.00+34.4%+365.8%$488.33M$1.05B-0.791,600Upcoming EarningsShort Interest ↓LXRXLexicon Pharmaceuticals1.9435 of 5 stars$1.80-2.2%$8.00+344.4%-9.0%$443.23M$1.20M-2.31285Analyst ForecastNews CoverageGap DownXOMAXOMA4.2571 of 5 stars$29.51+0.0%$78.50+166.0%+58.8%$343.47M$9.81M-11.8510Upcoming EarningsSGMOSangamo Therapeutics1.9277 of 5 stars$1.50+0.7%$2.67+77.8%+218.2%$311.27M$12.28M-1.09480Upcoming EarningsGap UpHigh Trading VolumeVNDAVanda Pharmaceuticals4.0554 of 5 stars$4.55+0.7%$13.00+185.7%+6.6%$265.22M$192.64M-23.95203Upcoming EarningsAnalyst ForecastAnalyst RevisionNews CoverageRIGLRigel Pharmaceuticals2.2611 of 5 stars$14.16-1.9%$31.13+119.8%+78.1%$248.62M$130.30M-16.46147Upcoming EarningsCDXSCodexis4.2352 of 5 stars$2.91-2.7%$8.75+200.7%+110.8%$205.32M$60.89M-2.69250Short Interest ↓News CoverageGap UpACHVAchieve Life Sciences0.7717 of 5 stars$4.71+0.4%$15.50+229.1%+10.3%$161.75MN/A-4.2420Upcoming Earnings Related Companies and Tools Related Companies MEI Pharma Alternatives Epizyme Alternatives Emergent BioSolutions Alternatives Lexicon Pharmaceuticals Alternatives XOMA Alternatives Sangamo Therapeutics Alternatives Vanda Pharmaceuticals Alternatives Rigel Pharmaceuticals Alternatives Codexis Alternatives Achieve Life Sciences Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:VSTM) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredNothing can stop this gold rallyAfter what's felt like nearly a decade of disappointing gains, gold is stronger than ever and continues to hit...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verastem, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Verastem With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
